Allergan Receives Pan European License for GANFORT(R) (LUMIGAN(R)/Timolol Combination) from European Commission

"We are extremely pleased with the European Commission's approvalof GANFORT(R), which enables Allergan to provide physicians andpatients throughout Europe with a once-daily, highly-effective andwell-tolerated form of combination therapy for glaucoma," said ScottWhitcup, M.D., Allergan's Executive Vice President, Research andDevelopment.

GANFORT(R) is indicated for the reduction of intraocular pressure(IOP) in patients with open-angle glaucoma or ocular hypertension whoare insufficiently responsive to topical beta-blockers orprostaglandin analogues. A fixed combination of bimatoprost 0.03% andtimolol maleate 0.5%, GANFORT(R) offers powerful IOP-lowering efficacycomparable to the free combination of these two agents, and greaterefficacy than monotherapy with either agent used alone. GANFORT(R)also provides clinically important IOP control in a once-daily dose,which is important for enhancing patient compliance - a key factor incontrolling glaucoma, a leading cause of preventable blindnessworldwide. In clinical trials, GANFORT(R) also had a superiortolerability profile, including 40 percent less hyperemia compared tobimatoprost monotherapy.

About Allergan, Inc.

Allergan, Inc., with headquarters in Irvine, California, is atechnology-driven, global health care company providing specialtypharmaceutical and medical device products worldwide. Allergandevelops and commercializes products in the ophthalmology,neurosciences, medical dermatology, medical aesthetics and otherspecialty markets that deliver value to its customers, satisfy unmetmedical needs, and improve patients' lives.

Forward-Looking Statements

This press release contains "forward-looking statements,"including, among other statements, the statements by Dr. Whitcup,statements regarding research and development outcomes, efficacy, andmarket and product potential. These statements are based on currentexpectations of future events. If underlying assumptions proveinaccurate or unknown risks or uncertainties materialize, actualresults could vary materially from Allergan's expectations andprojections. Risks and uncertainties include general industry andpharmaceutical market conditions; general domestic and internationaleconomic conditions, such as interest rate and currency exchange ratefluctuations; technological advances and patents obtained bycompetitors; challenges inherent in product marketing such as theunpredictability of market acceptance for new pharmaceutical andbiologic products and/or the acceptance of new indications for suchproducts; domestic and foreign health care reforms; the timing anduncertainty of the research and development and regulatory processes;trends toward managed care and health care cost containment; andgovernmental laws and regulations affecting domestic and foreignoperations. Allergan expressly disclaims any intent or obligation toupdate these forward-looking statements except as required to do so bylaw.

Additional information concerning these and other risk factors canbe found in press releases issued by Allergan, as well as Allergan'spublic periodic filings with the Securities and Exchange Commission,including the discussion under the heading "Risk Factors" inAllergan's 2005 Form 10-K and Allergan's Form 10-Q for the quarterended March 31, 2006. Copies of Allergan's press releases andadditional information about Allergan is available on the World WideWeb at www.allergan.com or you can contact the Allergan InvestorRelations Department by calling 1-714-246-4636.